CTRI/2010/091/000144已完成3 期
A randomised, double-blind, double-dummy, multi-centre, comparative parallel-group study to evaluate the efficacy and safety of oral daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the treatment of acute infectious diarrhoea in travellersAcronym ERASE
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,032
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients who meet all of the following criteria can be enrolled into the study:
- •1. Signed informed consent,
- •2. Men or women between 18 and 85 years of age
- •3. History of arriving from their country of residence in the industrialized part of the world within the past 4 weeks
- •4. Presenting with acute infectious diarrhoea (defined as at least 3 unformed, watery or soft, stools accompanied by symptoms within 24 hours preceding randomisation with duration of illness <= 72 hours) and able to provide an unformed stool sample during screening (and the latter can be the third unformed stool passed by the patient in the 24 hours prior to randomization). The bacterial origin of diarrhoea will be examined â??a posterioriâ?? by stool microbiology sampling at the time of screening,
- •5. Presence of one or more signs or symptoms of enteric infection (moderate to severe gas/flatulence, nausea, vomiting, abdominal cramps or pain, rectal tenesm, fecal urgency),
- •6. Women of child-bearing potential have to apply during the entire duration of the study a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, some IUDs, sexual abstinence or vasectomised partner. Note: The oral contraceptive method is ineffective in presence of diarrhoea and hormonal contraceptives could be inactivated in the presence of CYP inducers, such as Rifamycin SV. The investigator is responsible for determining an adequate method for birth control which the patient must agree to use.
排除标准
- •Patients who meet one of the following criteria are not allowed to be enrolled into the study:
- •1. US-American, Canadian, Australian and Indian (insurance, administrative and epidemiological reasons),
- •2. Residency in any country with a high incidence rate of travellerâ??s diarrhoea within the past six months
- •3. Fever (defined as a body (oral) temperature >100.4°F or 38.0°C; antipyretic medication should not be administered in the 6 hours prior to this assessment)
- •4. Known or suspected infection with non-bacterial pathogen,
- •5. Presence of diarrhoea of >72 hours duration,
- •6. Presence of grossly bloody stool,
- •7. Presence of moderate or severe dehydration (i.e. symptoms of hypovolemia such as orthostatic hypotension, dizziness or wrinkling of skin),
- •8. History of inflammatory bowel disease (IBD) and celiac disease,
- •9. Greater than two doses of an anti-diarrhoeal medication (e. g., antimotility, absorbent or antisecretory) within 24 hours before randomisation,
- •10. Receiving antibacterial drug with expected activity against gram negative bacterial pathogens (i. e., trimethoprim-sulfamethoxazole, fluoroquinolone, azithromycin or rifaximin) within 7 days prior to enrolment,
- •11. History or clinical evidence of severe impairment of liver and renal function,
- •12. Known intolerance/hypersensitivity/resistance to study drugs or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drugs,
- •13. Doubt about the patientâ??s cooperation, e.g., because of addiction to alcohol or drugs, mental illness, travel schedule,
- •14. Females, with existing or intended pregnancy or breast-feeding, or not using adequate birth control,
- •15. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial,
- •16. Treatment with tizanidine,
- •17. History of tendon disease / disorder related to quinolone treatment,
- •18. History or clinical evidence of central nervous disorders which may be disposed to seizures,
- •19. Risk for torsades de pointes arrhythmia,
- •20. History or clinical evidence of gastrointestinal obstructions, perforations in the gastrointestinal tract, or severe intestinal ulcerative lesions.
研究者
相似试验
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs Rifamycin SV-MMX® 600 mg b.i.d. three times daily vs placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-ITDr. Falk Pharma GmbH375
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-RODr. Falk Pharma GmbH201
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-LVDr. Falk Pharma GmbH375
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-DEDr. Falk Pharma GmbH375
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-SKDr. Falk Pharma GmbH375